

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-15. (cancelled)

16. (currently amended) ~~A substantially pure or isolated antigenic~~ An isolated polypeptide, ~~which binds to said binding composition of claim 11, and further comprises~~ comprising at least 17 contiguous amino acids from SEQ ID NO:2, 4, 6, or 8.

17.-25. (cancelled)

26. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 20 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.

27. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 25 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.

28. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 30 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.

29. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 35 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.

30. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 50 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.

31. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises at least 75 contiguous amino acid residues of SEQ ID NO: NO:2, 4, 6, or 8.

32. (new) An isolated polypeptide of claim 16, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, 4, 6, or 8.
33. (new) An isolated polypeptide of claim 16, wherein the polypeptide is detectably labeled.
34. (new) An isolated polypeptide of claim 16, wherein the polypeptide binds to a cell surface receptor.
35. (new) An isolated polypeptide of claim 34, wherein the cell surface receptor is an IL-12R-like subunit.
36. (new) An isolated polypeptide of claim 35, wherein the IL-12R-like subunit is WSX-1/TCCR.
37. (new) An isolated polypeptide of claim 16, wherein the polypeptide is antigenic.
38. (new) An isolated polypeptide comprising an amino acid sequence at least about 80% identical to SEQ ID NO:2, 4, 6, or 8.
39. (new) The polypeptide of claim 38, wherein the amino acid sequence comprises a sequence at least about 90% identical to SEQ ID NO:2, 4, 6, or 8.
40. (new) A composition comprising a polypeptide comprising at least 20 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8 and a pharmaceutically acceptable carrier.
41. (new) A method of modulating an immune response in a subject comprising:

administering to a subject an effective amount of a polypeptide comprising at least 17 contiguous amino acids of SEQ ID NO:2, 4, 6, or 8, wherein the polypeptide has an immunomodulatory effect.

42. (new) The method of claim 41, wherein the subject is a human.
43. (new) The method of claim 41, wherein the subject has an immune disorder.
44. (new) The method of claim 41, wherein the polypeptide comprises at least 20 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
45. (new) The method of claim 41, wherein the polypeptide comprises at least 25 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
46. (new) The method of claim 41, wherein the polypeptide comprises at least 30 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
47. (new) The method of claim 41, wherein the polypeptide comprises at least 35 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
48. (new) The method of claim 41, wherein the polypeptide comprises at least 50 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
49. (new) The method of claim 41, wherein the polypeptide comprises at least 75 contiguous amino acid residues of SEQ ID NO:2, 4, 6, or 8.
50. (new) The method of claim 41, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2, 4, 6, or 8.